Peripheral neuropathy decisions — 2025

The Board granted service connection for diabetic neuropathy and hypertension under the PACT Act, but remanded claims for service connection for a stroke and hypertension on direct or secondary basis.

The Board remands the issues of entitlement to a rating higher than 20 percent for peripheral neuropathy, left and right lower extremities, due to a pre-decisional duty to assist error.

The Board denied the veteran's claims for increased ratings and initial compensable ratings for prostate cancer, erectile dysfunction, left lower extremity peripheral neuropathy, and right lower extremity peripheral neuropathy.

The Board granted service connection for a neurological disability, to include peripheral neuropathy and/or chronic inflammatory demyelinating polyneuropathy (CIDP), due to in-service Agent Orange exposure.

The Veteran's psychiatric disability was granted a 100 percent rating, and special monthly compensation (SMC) at the housebound rate was also granted from March 31, 2011.

The Board granted increased disability ratings of 40 percent for both the left and right lower extremity diabetic peripheral neuropathy, effective May 27, 2022, as well as a total disability rating based on individual unemployability from that date.

The Board granted service connection for right and left lower extremity peripheral neuropathy, sciatic nerve, with effective dates of June 8, 2015 and November 19, 2018 respectively. The Board also granted a rating of 40 percent for IVDS with degenerative arthritis of the lumbar spine as of March 24, 2022.

The Board granted a rating of 20 percent for left knee chondromalacia but denied service connection for body arthritis and left lower extremity neuropathy. The claims for service connection for left hip/knee disability and right hip disability were remanded.

The Veteran's osteomyelitis of the left foot is granted a 60 percent rating, but no higher. The claim for a rating in excess of 10 percent for peripheral neuropathy of the left lower extremity, femoral nerve, is denied.

The Board denied the veteran's claims for earlier effective dates, increased ratings, and a compensable rating for erectile dysfunction.

The Board remands the claims for service connection for chronic inflammatory demyelinating polyneuropathy and sleep apnea to correct pre-decisional duty to assist errors.

The Board denied service connection for bilateral sensorineural hearing loss and remanded the claims for other conditions due to insufficient evidence.

The Board granted service connection for peripheral neuropathy in all four extremities, based on the Veteran's exposure to herbicide agents during his service in Vietnam.

The Board dismissed the appeals for ratings in excess of 20 percent for peripheral neuropathy (all radicular groups) with carpal tunnel syndrome, right and left upper extremities, since February 8, 2022.

The Board denied service connection for bilateral upper and lower extremity peripheral neuropathy as the evidence did not support a finding that these conditions began during active service or are otherwise related to an in-service injury, event, or disease.

The Board remands the claim for compensation under 38 U.S.C. § 1151 for residuals of ovarian cancer due to alleged negligent care, as a corrective opinion is needed.

The Board remands the claims for service connection for bilateral upper and lower extremity peripheral neuropathy due to a lack of a nexus opinion.

The Board granted service connection for dizziness associated with the Veteran's service-connected neck condition and tension headaches, as well as left and right lower extremity neuropathy.

The Board granted service connection for type 2 diabetes mellitus, right and left upper and lower extremity idiopathic polyneuropathy, effective from April 20, 2015. The seizure disorder claim was remanded.

The Board denied service connection for right and left lower extremity peripheral neuropathy, finding no relationship between the conditions and active service.